Medical device company CardioNXT and AFTx on Wednesday jointly announced full enrolment of 65 treated patients under the Real-time electrogram Analysis for Drivers of Atrial fibRillation (RADAR) clinical trial.

According to the companies, the RADAR trial focuses on treating patients with Persistent and Long Standing Persistent Atrial Fibrillation (AF).

This trial evaluates a novel high resolution contact mapping technology to identify tissue within the heart that causes AF. The mapping technology generates an image of the heart that cardiac electrophysiologists use to tailor patient specific therapy, added the companies.

Mapping Atrial Fibrillation may enable the company to tailor therapy appropriately for each and every patient with Persistent and Long Standing Persistent Atrial Fibrillation. Mapping Atrial Fibrillation efficiently with simple, safe, contact based catheters is especially important, said Vivek Reddy, MD, director of Cardiac Arrhythmia Service at Mount Sinai Hospital in New York, NY.